KEPP, Kasper P; HOILUND-CARLSEN, Poul F; CRISTEA, Ioana A; CUMMING, Robert G; DALY, Timothy; EMILSSON, Louise; FLACCO, Maria E; HEMKENS, Lars G; JANIAUD, Perrine; JOHNSEN, Kasper B; LALLUKKA, Tea; MUKA, Taulant; NAUDET, Florian; REVHEIM, Mona-Elisabeth R; SQUITTI, Rosanna; THAMBISETTY, Madhav

doi:10.1080/03007995.2025.2458530

Metadatos

Mostrar el registro completo del ítem

Licencia de uso del documento

Idioma

Article de revue

Este ítem está publicado en

Current Medical Research and Opinion. 2025-02-05, vol. 41, n° 2, p. 347-354

Resumen en inglés

This paper reviews the scientific evidence on new anti-amyloid monoclonal antibodies for treating Alzheimer's disease as a case study for improving scientific evidence communication. We introduce five guidelines condensed from the biomedical evidence literature but adapted to the short format of science communication in e.g., journal opinion pieces and newspaper articles. Given the major importance and recent confusion regarding the discussed drugs, with certain disagreements seen e.g., between FDA and EMA, the suggested guidelines may be useful to clinicians discussing with their patients and to scientists communicating the evidence in balance. More generally, we hope that the guidelines may help us to improve communication of scientific evidence on complex topics in opinion pieces in the scientific literature, in advocacy, and in media appearances.< Leer menos

Palabras clave en inglés

Alzheimer’s Disease

Evidence

Donanemab

Health Policy

Lecanemab

Science Communication

Metadatos

Compartir este ítem

Licencia de uso del documento

Communicating scientific evidence: drugs for Alzheimer's disease as a case study

Idioma

Este ítem está publicado en

Resumen en inglés

Palabras clave en inglés

URI

DOI

Centros de investigación